Abstract
Cardiovascular disease is the leading complication of diabetes mellitus (DM), and diabetic cardiomyopathy (DCM) is a major cause of mortality in diabetic patients. Multiple pathophysiologic mechanisms, including myocardial insulin resistance, oxidative stress and inflammation, are involved in the development of DCM. Recent studies have shown that mitochondrial dysfunction makes a substantial contribution to the development of DCM. Mitophagy is a type of autophagy that takes place in dysfunctional mitochondria, and it plays a key role in mitochondrial quality control. Although the precise molecular mechanisms of mitophagy in DCM have yet to be fully clarified, recent findings imply that mitophagy improves cardiac function in the diabetic heart. However, excessive mitophagy may exacerbate myocardial damage in patients with DCM. In this review, we aim to provide a comprehensive overview of mitochondrial quality control and the dual roles of mitophagy in DCM. We also propose that a balance between mitochondrial biogenesis and mitophagy is essential for the maintenance of cellular metabolism in the diabetic heart.
Highlights
Diabetes mellitus (DM) is one of the most common chronic diseases and places a substantial burden on public health worldwide
We aim to provide a comprehensive overview of mitochondrial quality control and the dual roles of mitophagy in Diabetic cardiomyopathy (DCM)
It is clear that mitophagy plays a central role in the regulation of mitochondrial quality control in DCM and that the regulation of mitophagy represents a promising potential therapeutic strategy for this complication
Summary
Diabetes mellitus (DM) is one of the most common chronic diseases and places a substantial burden on public health worldwide. There are ∼451 million patients with DM worldwide and it is predicted that this number will rise to 693 million by 2045 (Cho et al, 2018). Cardiovascular complications are the leading cause of mortality associated with DM, accounting for 50–80%. Mitophagy in Diabetic Cardiomyopathy of deaths (Rawshani et al, 2017). Diabetic cardiomyopathy (DCM) is a non-ischemic and non-hypertensive cardiomyopathy that is caused by diabetic metabolic disorders (Maack et al, 2018). DCM is characterized by diastolic dysfunction and left ventricular hypertrophy, and systolic dysfunction develops in the middle or late stages of DCM, and can be associated with myocardial fibrosis and apoptosis (Marwick et al, 2018)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
